An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Dayvigo

Chemical Namelemborexant
Dosage FormTablet (oral; 5 mg, 10 mg)
Drug ClassReceptor antagonists
SystemNervous
CompanyEisai Inc.
Approval Year2019

Indication

  • Dayvigo is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Dayvigo (lemborexant) Prescribing Information2020Eisai
Document TitleYearSource
Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis.2020Journal of Psychiatric Research
Pharmacotherapies for sleep disturbances in dementia.2020Cochrane Database of Systematic Reviews